Vessi Medical is developing an innovative, IP protected cryo spray for hollow & humid organs, a new approach in the treatment of Non Muscle Invasive Bladder Cancer (NMIBC).
Vessi’s first indication, low-grade NMIBC is account for around 50% of bladder cancer patients.
First in human study (FIH) clinical trials initiated 2021.
Recurrent disease, that necessitate repeat treatments, with reduced quality of life
Transurethral Resection of Bladder Tumor (TURBT) is the leading first-line therapy. A costly, invasive surgical procedure, TURBT is performed in a hospital under general anesthesia, with significant complications. Moreover, in up to 80% of cases the cancer returns, and that results in multiple repeat procedures which further reduce patients’ quality of life.
Vessi’s initial target is the
$1.2 billion NMIBC market
Most common cancer
75% of all bladder cancers
1.7 million suffer globally
570,000 new cases every year!
NMIBC is defined as a cancer on the surface of the inner lining of the bladder. Physical symptoms often include problems urinating, pain and blood in the urine, or sexual dysfunction; however, it may also affect mental health and lead to a significant decrease in quality of life.
The standard of care has numerous limitations
Bleeding (14.1%) and perforations (4.7%) with frequent extraperitoneal extravasation of urine
Residual tumors 2cm around visible tumor, in 13% of Ta and in 35% of T1 tumors
50%-80% Recurrences after TURBT, most during the first year
Unique cryo spray for hollow & humid organs
Vessi's minimally invasive solution for NMIBC provides a new therapeutic alternative to surgery. The company's bladder-specific cryotherapy reduces the cost and the complications associated with TURBT.
Easy to use
Potentially no anesthesia, office procedure
THE VESSI SYSTEM
The Vessi system consists of a standalone console and a disposable device that is inserted transurethrally into the bladder.
Visualization in liquids & gases mix environment
Visualization inside hollow organs during surface cryotherapy
potential no anesthesia
Balances the ideal cooling temperature & pressure
POTENTIALLY NO ANESTHESIA, OFFICE PROCEDURE
‘Freeze’ and remove bladder cancer tumors, 2021
Vessi Medical Reports 1st in Human, 2021
activation and completion, without complications
FIH Procedure with Vessi Medical's, 2021
Vessi announced that it successfully completed a first-in-human case with its minimally invasive cryoablation
Vessi Medical completes $1.7 million in funding, 2020
Founder & CEO
Seasoned medical device manager with vast cryotherapy experience; prior positions with Motus GI, Galil Medical, Given Imaging; MSc, MBA, Technion Israel institute of Technology
Years of experience in pneumatics, fine mechanics, and cryogenics; prior position in the defense industry
Engineering leader at ET View, R&D development at Motus GI; experience in medical device V&V process, transfer to production and early stages development
Prof. Gilad E. Amiel,
Chairman, Department of Urology, Rambam Health Care Campus, Israel; adjunct Associate Professor of Urology, Baylor College, Houston, Texas; former President of the American Association for Cancer Education (AACE)
Dr. Benny Zeevi, MD
Venture capitalist deeply involved in the Israeli life sciences over 20 years. A certified Pediatric Cardiologist, was Director of Pediatric Catheterization Unit, Schneider Children's, and Professor and part-time clinical staff at the Children's Hospital, Harvard, Boston